'Embarrassing'
or stigmatized cancers like lung and liver are underfunded
Northwestern
University
Many
of the deadliest or most common cancers get the least amount of nonprofit
research funding, according to a new Northwestern Medicine study that examined
the distribution of nonprofit research funding in 2015 across cancer types.
Colon,
endometrial, liver and bile duct, cervical, ovarian, pancreatic and lung
cancers were all poorly funded compared to how common they are and how many
deaths they cause, the study found. In contrast, breast cancer, leukemia,
lymphoma and pediatric cancers were all well-funded, respective to their impact
on society.
The study is the
first to compare nonprofit funding distribution in the United States across
cancer types. It will be published July 18 in the Journal of the National Comprehensive Cancer
Network.
"The goal of this study is not to divert funds away from cancers that are well-supported, but rather expand funding for other cancers that aren't getting enough support currently," said corresponding author Dr. Suneel Kamath, who was the chief fellow in the department of hematology and oncology at Northwestern University Feinberg School of Medicine when he conducted the study. "These are all deadly and life-altering diseases that deserve our attention and support."
Cancer-related
nonprofit organizations play an important role in funding medical research,
supporting the education of patients and their families and influencing health
policy. Underfunding of these common cancers could negatively impact research,
drug development and the number of FDA drug approvals for poorly funded
cancers.
"Well-funded
patient advocacy organizations should be applauded for their successes,"
said co-author Dr. Sheetal Kircher, assistant professor of hematology and
oncology at Feinberg and a Northwestern Medicine oncologist. "We hope to
bring awareness to the organizations with less relative funding so we can
collaborate to improve funding and outcomes for all patients with cancer."
The study also
explored factors that may influence which cancers receive more public support
over others. Cancers that are associated with a stigmatized behavior, such as
lung cancer with smoking or liver cancer with drinking, were all poorly funded.
"Shame and
discomfort with talking about our bowels and 'private parts' may be reducing
funding for diseases like colon or endometrial cancer," Kamath said.
The nationwide
study, conducted between October 2017 and February 2018, used IRS tax records
to identify all nonprofit organizations that support any type of cancer and
made at least $5 million in annual revenue in 2015.
The scientists examined 119 organizations with a total of $5.98 billion in annual revenue. Most of this ($4.59 billion) went to general cancer charities with no focus on one disease (e.g. American Cancer Society).
The scientists examined 119 organizations with a total of $5.98 billion in annual revenue. Most of this ($4.59 billion) went to general cancer charities with no focus on one disease (e.g. American Cancer Society).
The authors
compared the amount of revenue for each cancer type with the number of new
cases, number of deaths and number of years of life lost to see if the amount
of funding for each cancer is proportional to how common and/or deadly it is.
Dr. Al Benson,
professor of hematology and oncology at Feinberg and a Northwestern Medicine
oncologist, also is a study author. Benson and Kircher also are members of the
Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
The study was
not funded or supported by any government, nonprofit or industry entities.